DE MERCANTI, STEFANIA FEDERICA

DE MERCANTI, STEFANIA FEDERICA  

SCIENZE CLINICHE E BIOLOGICHE  

Mostra records
Risultati 1 - 20 di 75 (tempo di esecuzione: 0.02 secondi).
Titolo Data di pubblicazione Autore(i) File
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome 2009 Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 2017 Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View 2019 Maglione, Alessandro; Rolla, Simona; Mercanti, Stefania Federica De; Cutrupi, Santina; Clerico, Marinella
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 2016 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 2016 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 2016 De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 2012 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
ALS patients and caregivers communication preferences and information seeking behaviour 2008 CHIÒ A; MONTUSCHI A; CAMMAROSANO S; DE MERCANTI S; CAVALLO E; ILARDI A; GHIGLIONE P; MUTANI R; CALVO A.
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 2018 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study 2014 A. Chiò;A. Calvo;G. Bovio;A. Canosa;D. Bertuzzo;F. Galmozzi;P. Cugnasco;M. Clerico;S. De Mercanti;E. Bersano;S. Cammarosano;A. Ilardi;U. Manera;C. Moglia;R. Sideri;K. Marinou;E. Bottacchi;F. Pisano;R. Cantello;L. Mazzini;G. Mora; Piemonte;V. d. Register
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study 2015 Calvo, A; Moglia, C; Canosa, A; Bertuzzo, D; Galmozzi, F; Cugnasco, P; Clerico, M; De Mercanti, S; Bersano, E; Cammarosano, S; Ilardi, A; Manera, U; Sideri, R; Marinou, K; Bottacchi, E; Pisano, F; Cantello, R; Mazzini, L; Mora, G; Chiò, A
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question 2020 De Mercanti S.F.; Gned D.; Matta M.; Iudicello M.; Franchin E.; Clerico M.
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 2015 De Mercanti, S; Artusi, Ca; Clerico, M; Iudicello, M; Vacca, A; Virgilio, E; Durelli, L
Atypical presentation of superficial sclerosis successfully treated with iron chelation 2013 De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study 2015 Barbero, P; Artusi, Ca; De Mercanti, S; Tinivella, M; Busso, M; Clerico, M; Durelli, L
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study 2019 Artusi, Carlo Alberto; Bortolani, Sara; Merola, Aristide; Zibetti, Maurizio; Busso, Marco; De Mercanti, Stefania; Arnoffi, Paolo; Martinetto, Simone; Gaidolfi, Elena; Veltri, Andrea; Barbero, Pierangelo; Lopiano, Leonardo
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? 2010 Luca Durelli; Marinella Clerico; Simona Rolla; Giulia Contessa; Stefania De Mercanti; Antoni Uccelli; Mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; Roberto Cavallo; Luisa Sosso; Francesco Novelli
Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series 2021 De Mercanti S.F.; Vercellino M.; Bosa C.; Alteno A.; Schillaci V.; Clerico M.; Cavalla P.
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 2017 Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S.
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 2016 De Mercanti, S; Durelli, L; Iudicello, M; Artusi, Ca; Barbero, P; Guerrasio, A; Clerico, M